Key facts
- It has raised $21.4M; the latest was Later Stage VC ($14.3M) in Mar 2026.
- Notable investors include Shinhan Venture Investment, HG Initiative, SJ Investment Partners, iM Investment Partners, UTC Investment — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Ticaros
- ·The full record, as it builds
Funding rounds
No funding rounds for Ticaros are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ticaros
Developer of CAR-T cell therapy intended to treat patients with relapsed and refractory cancer. The company's technology enhances the efficacy of T cells by selectively inhibiting CTLA4 function only to cancer-specific T cells and increases the ability to eliminate tumors by modifying the CAR construct to make more CAR-T cells bind to tumor cells, enabling patients to avail novel cancer treatment.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2018
- Employees
- 26
- Website
- ticaros.com/
- Ownership
- Privately Held (backing)
Ticaros doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ticaros shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ticaros in its N-PORT filings yet. We sweep new filings monthly.